---
layout: post
title: "Acrotech Biopharma LLC; Withdrawal of Approval of New Drug Application for MARQIBO (VinCRIStine Sulfate LIPOSOME Injection), 5 milligrams/5 milliliters"
date: 2026-02-05 18:59:00 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-09235
original_published: 2022-05-02 00:00:00 +0000
significance: 8.00
---

# Acrotech Biopharma LLC; Withdrawal of Approval of New Drug Application for MARQIBO (VinCRIStine Sulfate LIPOSOME Injection), 5 milligrams/5 milliliters

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 02, 2022 00:00 UTC
**Document Number:** 2022-09235

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) for MARQIBO (vinCRIStine sulfate LIPOSOME injection), 5 milligrams (mg)/5 milliliters (mL), held by Acrotech Biopharma LLC (Acrotech), 29 Princeton Hightstown Rd., East Windsor, NJ 08520. Acrotech has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/02/2022-09235/acrotech-biopharma-llc-withdrawal-of-approval-of-new-drug-application-for-marqibo-vincristine)
- API: https://www.federalregister.gov/api/v1/documents/2022-09235

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
